106 related articles for article (PubMed ID: 28834790)
1. Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer.
Aghaei A; Ayati N; Shafiei S; Abbasi B; Zakavi SR
Nucl Med Commun; 2017 Nov; 38(11):927-931. PubMed ID: 28834790
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
3. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.
Fallahi B; Beiki D; Takavar A; Fard-Esfahani A; Gilani KA; Saghari M; Eftekhari M
Nucl Med Commun; 2012 Mar; 33(3):275-82. PubMed ID: 22124360
[TBL] [Abstract][Full Text] [Related]
4. Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.
Yoo D; Ajmal S; Gowda S; Machan J; Monchik J; Mazzaglia P
World J Surg; 2012 Jun; 36(6):1255-61. PubMed ID: 22430670
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
[TBL] [Abstract][Full Text] [Related]
6. Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario.
Campennì A; Giovanella L; Pignata SA; Violi MA; Siracusa M; Alibrandi A; Moleti M; Amato E; Ruggeri RM; Vermiglio F; Baldari S
Nucl Med Commun; 2015 Nov; 36(11):1100-6. PubMed ID: 26302462
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ablation of thyroid remnants with 1850 MBq iodine-131 in 67 patients with thyroid cancer.
Kawabe J; Higashiyama S; Kotani K; Yoshida A; Onoda N; Shiomi S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):68-75. PubMed ID: 27125316
[TBL] [Abstract][Full Text] [Related]
8. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
[TBL] [Abstract][Full Text] [Related]
9. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131).
Prpic M; Dabelic N; Stanicic J; Jukic T; Milosevic M; Kusic Z
Ann Nucl Med; 2012 Nov; 26(9):744-51. PubMed ID: 22829399
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
12. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial.
Qu Y; Huang R; Li L
Ann Nucl Med; 2017 Jan; 31(1):71-83. PubMed ID: 27757803
[TBL] [Abstract][Full Text] [Related]
13. Chinese Data of Efficacy of Low- and High-Dose Iodine-131 for the Ablation of Thyroid Remnant.
Ma C; Feng F; Wang S; Fu H; Wu S; Ye Z; Chen S; Wang H
Thyroid; 2017 Jun; 27(6):832-837. PubMed ID: 28401794
[TBL] [Abstract][Full Text] [Related]
14. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study.
Mäenpää HO; Heikkonen J; Vaalavirta L; Tenhunen M; Joensuu H
PLoS One; 2008 Apr; 3(4):e1885. PubMed ID: 18382668
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy of 2220 MBq versus 3700 MBq I-131 for ablation of thyroid remnant in patients with differentiated thyroid cancer.
Fish SA; Basu S; Alavi A; Mandel SJ
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):560-3. PubMed ID: 20927023
[TBL] [Abstract][Full Text] [Related]
16. Implication of different clinical and pathological variables in patients with differentiated thyroid cancer on successful ablation for 3700 MBq (131)I: a single Egyptian institutional experience over 14 years.
Husseini MA
Ann Nucl Med; 2016 Aug; 30(7):468-76. PubMed ID: 27194041
[TBL] [Abstract][Full Text] [Related]
17. The predictive value for excellent response to initial therapy in differentiated thyroid cancer: preablation-stimulated thyroglobulin better than the TNM stage.
Zhang Y; Hua W; Zhang X; Peng J; Liang J; Gao Z
Nucl Med Commun; 2018 May; 39(5):405-410. PubMed ID: 29557849
[TBL] [Abstract][Full Text] [Related]
18. Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer.
M El-Refaei S; W Yassin S; Salman K; Al Munshy T; Al-Ezzi M; M Al-Sayed Y; Abd Elkareem Husseni M
Nucl Med Commun; 2015 Feb; 36(2):114-9. PubMed ID: 25350460
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
